
JC04 Rec'd PCT/PTO 27 SEP 2005



Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER PA/4-32908A						
TRANSMITTAL LETTER TO THE UNITED STATES		U.S. APPLICATION NO. (If known, see 37 CFR 1.6						
DESIGNATED/ELECTED OFFICE (DO/EO/US)		Not Yet Assigned						
CONCERNING A FILING UN		10/551218						
INTERNATIONAL APPLICATION NO. PCT/EP04/003368	INTERNATIONAL FILING DATE 30 March 2004 (30.03.04)	PRIORITY DATE CLAIMED 31 March 2003 (31.03.03)						
TITLE OF INVENTION ORAL SUSPENSION OF TEGASEROD								
APPLICANT(S) FOR DO/EO/US								
BIZOT ET AL.								
Applicant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) the	ne following items and other information:						
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest 								
claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is transmitted herewith (required only if not transmitted by the International Bureau). b. has been transmitted by the International Bureau. (See Form PCT/IB/308)								
 c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. 								
d. A have not been made and will 8. A translation of the amendments to t 9. An executed Declaration and Power 10. A translation of the annexes to the In U.S.C. 371(c)(5)).	he claims under PCT Article 19 (35 of Attorney (original or copy) (35 U.	S.C. 371(c)(4)).						
Items 11. to 16. below concern document	s) or information included.							
11. 🔀 An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
 An assignment document for recording included. 	ng. A separate cover sheet in comp	oliance with 37 CFR 3.28 and 3.31 is						
13. ☐ A FIRST preliminary amendment.☐ A SECOND or SUBSEQUENT preliminary	ninary amendment.							
14. An Application Data Sheet under 37	CFR 1.76.							
15. A substitute specification.								
16. A change of power of attorney and/o	r address letter.							
17. A computer-readable form of the sec 1.825.	uence listing in accordance with PC	T Rule 13ter.2 and 37 CFR 1.821-						
18. A second copy of the published Inter	national Application under 35 U.S.C	. 154(d)(4).						
19. A second copy of the English langua	ge translation of the International ap	oplication under 35 U.S.C. 154(d)(4).						
20. Other items or information: Post Car	d and Unexecuted Declaration.							

JC12 Rec'd PCT/PTC 27 SEP 2005

U.S. APPLICATION NO. (if Innown, see 37 FFT). 5 1 2 INTERNATIONAL APPLICATION NO. Not Yet Assigned 1075512 INTERNATIONAL APPLICATION NO.			PA/4-3290	DOCKET NUMBER 08A						
The following fe									ŪLATIOI	NS PTO USE
								ONLY		
21. 🛭 Basi	c nationa	l fee					\$300			
22. Examination Fee										
☐ If International preliminary examination report was prepared by USPTO										
and all claims satisfy provisions of PCT Article 33(1)-(4) \$										
. All other situations										
00 0										
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international										
application to the USPTO as an International Searching Authority \$										
☐ If International Search Report was prepared and provided to the Office										
23 7410	1101 31100									
				21, 22 AND 23 =				\$	1,000	
Additional fee for	or specific	cation and d	Irawings filed in	paper over 100 she	eets (ex	cluding s	equence listing	or comp	outer	
program listing thereof.	iiled in an	n electronic	medium). The	fee is \$250 for each	n additio	onai 50 sn	eets of paper of	rtractio	1	
Total Sheets	Extra	sheets	Number of ea	ch additional 50 or f	raction		RATE			
			thereof (round	l up to a whole num	ber)					
- 100 =	L	/50 =				X \$	250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than							s			
months from the		claimed pri	ority date (37 C	FR 1.492(e)).				Ľ.		
CLAIMS			ER FILED	NUMBER EXTR	A		RATE			
Total claims		15 3	- 20 =	0 0		X \$ X \$	50 200	\$		
Independent cla						^ *	360	\$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360 TOTAL OF ABOVE CALCULATIONS =						\$	1,000			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be						-				
filed (Note 37 CFR 1.9, 1.27, 1.28).					\$	1.000				
SUBTOTAL = Processing fee of \$130 for furnishing the English translation later than 30 months from the					\$	1,000				
earliest claimed				ansiation later than	□ 30	months	rom tne	\$		
Garrisot Glaritos	- p.101119 C			7	OTAL	NATIO	NAL FEE =	\$	1,000	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied										
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$				
				TO'	TAL F	EES EN	ICLOSED =	\$	1,000	
									nount to	\$
									efunded_ charged	¢
			-	4	6	il		<u> </u>	narged	Ψ
		amount of \$		to cover the abo						
b. 🔯 Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,000 to cover the above fees. A duplicate copy of this form is enclosed.										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
Deposit Account No. 12-0104 in the hante of Novaria.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
						d J. Wlus			X	$\overline{}$
Novarti					Áttorn	ey for App	olicants	_		ノ
Corporate Intellectual Property Reg. No. 52,370 One Health Plaza, Building 104 (862) 778-7960										
East Hanover, NJ 07936-1080										